TherapeuticsMD met with FDA officials one month ago but is still waiting for a resolution to the agency’s rejection of its estrogen therapy for postmenopausal women known as TX-004HR. The “regulatory update” announced Monday with no clear plan forward was not well received by investors. TherapeuticsMD shares are down 11 percent.

TX-004HR is a capsule filled with estradiol (bioidentical estrogen) that menopausal women insert into their vaginas to deal with the bothersome vaginal changes — dryness, itching, pain during sex — that can occur when the body’s own estrogen levels fall.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.